Soriano-Lorenzo JL, Zaldivar-Blanco K, Rojas APF, Peña VA, Lima PM, Soriano GJL

Language: Spanish
References: 35
Page: 260-269
PDF size: 342.60 Kb.

ABSTRACT

Introduction: Colorectal cancer is the third most frequent location and the fourth in cancer mortality. As in other neoplastic processes, the use of chemotherapy has great importance in its treatment.
Objective: To identify the adverse events presented in patients with colorrectal and anal cancer due to the use of antineoplastic chemotherapy in ambulatory setting.
Material and Methods: A cross-sectional, descriptive, observational study was conducted at the Oncology Service of the "Hermanos Ameijeiras" Hospital in Havana. The universe was determined by all patients diagnosed with colorectal and anal canal cancer treated in ambulatory setting during the period of January-June 2017, both months included (n = 152).
Results: The most used chemotherapy schedule was capecitabine in 48 % of patients. The greatest number of reports of hematological toxicity were due to anemia. The most frequent degrees of renal and hepatic toxicity were grade I. Regarding the incidence of nausea and vomiting, there were no significant differences. The chemotherapy schedule with the highest reported cases of diarrhea was XELOX.
Conclusions: The chemotherapy regimen that showed the highest hematological toxicity was capecitabine, and in the group of patients with ≥70 years, it was FLOX. The hepatic and renal toxicity was higher in those treated with FLOX, as in patients of ≥70 years. Diarrhea, nausea and vomiting were mostly produced by the XELOX scheme, and in the population of ≥70 years it was FLOX.

REFERENCES

1. Arnold M, Sierra M, Laversannel. Global patterns and trend in colorrectal cancer incidence and mortality. GUT. 2016;10:1-9.

2. Ferlay J, Soerjomataram I, Ervik M. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer; 2013.

3. Jemal A, Siegel R, Xu J. Cancer statistics, 2016. CA Cancer J Clin. 2017;60:277–300.

4. Ministerio de Salud Pública. Dirección de Registros médicos y estadísticas de salud. Anuario Estadístico de Salud 2016. Cuba: La Habana; 2017 [consultado el 15 de marzo de 2018].

5. Disponible en: http://bvscuba.sld.cu/anuario-estadistico-decuba/

6. Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, et al. Colorectal Cancer. Nat Rev Dis Primers [Internet]. 2015 [consultado el 15 de marzo de 2018]; 1: 15065. Disponible en: https://dx.doi.org/10.1038/nrdp.2015.65

7. Ferreiro J, García JL, Barcelo R, Rubio I. Quimioterapia: Efectos secundarios. Gac Med Bilb. 2003;100:69-74.

8. Blasco T, Inglés N. Calidad de vida y adaptacion a la quimoterapia en pacientes con cancer. Anuario Psicologia. 1997;72:81-90.

9. Blasco, T. y Bayés, R. Factores psicológicos en la tolerancia a los efectos secundarios de la quimioterapia. Clínica y Salud. 1990;1(2):133-141.

10. Aston WJ, Hope DE, Nowak AK, Robinson BW, et al. A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy. BMC Cancer. 2017;17:684-694.

11. Zietarska M, Krawczyk-Lipiec J, Kraj L, Zaucha; R Malgorzewicz. Chemotherapy-Related Toxicity, Nutricional status and quality of life in oncology patients, with or without, high protein nutricional support. A prospective, randomized study. Nutrients. 2017;9:1108-1120.

12. Bounkeua RF, Thumme G, Westfall TC. Principles of Antineoplastic Chemotherapy. En: Brunton L, Chabner B and Knollmann. Goldman and Gilman’s. The Pharmacological basis of the therapeutic. 12ma Ed. New York. McGraw-Hill. 2011.

13. Libutti SV, Saltz LB, Willett CG, and Levine RA. En: DeVitta, Hellman and Rosemberg. Cancer: Principles and practice of oncology. 10 Ed. Philadelphia: Lippincott Williams & Wilkins; 2015;p. 1526-1550.

14. Pearce A, Haas M, Viney R, Pearson S-A, Haywood P, Brown C, et al. Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study. PLoS ONE. 2017;12(10):1-12.

15. Wahlang JB, Laishram PD, Brahma DK, Sarkar C, Lahon J and Nongkynrih BS. Adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital. Ther Adv Drug Saf. 2017;8(2):61–66.

16. Chopra D, Rehan H, Sharma V, Mishra R. Chemotherapy-induced adverse drug reactions in oncology patients: a prospective observational survey. Ind J Med Paediatr Oncol. 2016;37:42–46.

17. Khandelwal S, Bairy L, Vidyasagar M, Chogtu B, Sharan K. Adverse drug reaction profile of cancer patients on chemotherapy in a tertiary care hospital. Int J Pharm Bio Sci. 2015;6:233–244.

18. Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastasic colorectal cancer. Ann Oncol. 2018;29: 44-70.

19. Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, Arnold D, et al. Rectal Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol [Internet]. 2017 [consultado el 16 de marzo de 2018];28(Suppl 4):22-40. Disponible en: http://www.kosmidisoncology.com/img/551175153f60a6c6438e783cbecf31faGUIDELINES%20FOR%20RECTAL%20CANCER.full.pdf

20. Twelves C, Wong A, Nowacki MP. Capecitabine as adjuvant treatment for stage III colon cancer. N Eng J Med. 2005;352:2696–2704.

21. Suto T, Ishiguro M, Hamada C, Kunieda K, Masuko H. Preplaned saety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer. Int J Clin Oncol. 2017;22:494-504.

22. Vincent MD, Breadner D, Cripps MC, Jonker DJ, Klimo P. Phase I/II trial of dose-reduced capecitabine in elderly patients with advanced colorectal cancer. Curr Oncol [Internet]. 2017 [consultado el 16 marzo de 2018];24(4):e261-e268. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576465/

23. Seymour MT, Thompson LC, Wasan HS. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (mrc focus2): an open-label, randomised factorial trial. Lancet Oncol. 2011;377:1749–59.

24. Cassidy J, Tabernero J, Twelves C. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004;22:2084–91.

25. Diaz-Rubio D, Evans TR, Tabemero J, Cassidy J, Sastre J, Eatock M, et al. Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol. 2002;13(4):558-65.

26. Chiu J, Tang V, Leung R, Wong H, Chu KW. Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in asian patients with colorectal cancer: 4-year analysis. Asian Pac J Cancer Prev. 2013;14(11):6585-6590.

27. Kawakami K, Yokokawa T, Kobayashi K, Sugisaki T. Self-reported adherence to capecitabine on XELOX treatment as adjuvant therapy for colorectal cancer. Oncol Research. 2017; 25:1625–1631.

28. Pectasides D, Karavasilis V, Papaxoinis G, Gourgioti G, Makatsoris T. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer. BMC Cancer [Internet]. 2015 [consultado el 16 de marzo de 2018];15:348. Disponible en: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1406-7

29. Leonardi S, Sobrero A, Rosati G, Di Bartolomeo M, Ronzoni M, Aprile G, et al. Phase III trial comparing 3-6 months of adjuvant FOLFOX/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. Ann of Oncol. 2016;27:2074-2081.

30. Park YS, Ji J, Zalcberg JR, Mostafa EL, Serafi AE, Buzaid A, et al. Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry. Asian-Pacific J Clin Oncol. 2015;11:334-342.

31. Schmoll HJ, Twelves C, Sun W, O’Conell MJ, Cartwright T, McKenna E, et al. Effect of adjuvant Capecitabine or Fluorouracil, with or without Oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatino on post-relapse survival: A pooled analysis of individual patient data from four randomized trials. Lancet Oncol. 2014;15(13):1481-1492.

32. De Felice F, Musio D, Magnante AL, Bulzonetti N, Benevento I, Caiazzo R, Tombolini V. Disease control, survival, and toxicity outcome after intensified neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a single-institution experience. Clin Colorectal Cancer. 2016;28(3):18–24.

33. De Felice F, Benevento I, Magnante AL, Musio D, Bulzonetti N, Caiazzo R, et al. Clinical benefit of adding oxaliplatin to standard neoadjuvant chemo-radiotherapy in locally advanced rectal cancer: a meta-analysis. BMC Cancer. 2017;17:325.

34. Lund CM, Nielsen D, Dehlendorff C. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colorectal cancer: the ACCORE study. ESMO Open. 2016;1:e000087.

35. Sanoff HK, Carpenter WR, Stürmer T. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol. 2012;30:2624–34.